London, Feb 20 (Ians) A three-month interval between doses of the Oxford University-AstraZeneca vaccine resulted in higher vaccine efficacy than a six-week interval, reveals The Lancet study.
According to the findings from a phase 3 randomised controlled trial, the first dose offered 76 per cent protection in the three months between doses.
The interval between doses can be safely extended to three months given the protection a single dose offers, which may allow countries to vaccinate a larger proportion of the population more rapidly, the researchers said.
"Where there is a limited supply, policies of initially vaccinating more people with a single dose may provide greater immediate population protection than vaccinating half the number of people with 2 doses," said lead author Andrew Pollard from the University of Oxford, UK.
"In the long term, a second dose should ensure long-lived immunity, and so we encourage everyone who has had their first vaccine...
According to the findings from a phase 3 randomised controlled trial, the first dose offered 76 per cent protection in the three months between doses.
The interval between doses can be safely extended to three months given the protection a single dose offers, which may allow countries to vaccinate a larger proportion of the population more rapidly, the researchers said.
"Where there is a limited supply, policies of initially vaccinating more people with a single dose may provide greater immediate population protection than vaccinating half the number of people with 2 doses," said lead author Andrew Pollard from the University of Oxford, UK.
"In the long term, a second dose should ensure long-lived immunity, and so we encourage everyone who has had their first vaccine...
- 2/20/2021
- by Glamsham Bureau
- GlamSham
London, Feb 4 (Ians) A vaccine to tackle the Covid-19 variants could be ready by autumn, the Oxford-AstraZeneca team said.
"I think the actual work on designing a new vaccine is very, very quick because it's essentially just switching out the genetic sequence for the spike protein," said Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial, in a media briefing hosted by AstraZeneca.
"And then there's manufacturing to do and then a small scale study. So all of that can be completed in a very short period of time, and the autumn is really the timing for having new vaccines available for use," he added.
According to the BBC, the team was already looking at updating the vaccine to make it more effective against the mutations that are being seen.
It comes after studies have shown that variants of Covid-19 with the worrying E484K mutation could make vaccines less effective,...
"I think the actual work on designing a new vaccine is very, very quick because it's essentially just switching out the genetic sequence for the spike protein," said Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial, in a media briefing hosted by AstraZeneca.
"And then there's manufacturing to do and then a small scale study. So all of that can be completed in a very short period of time, and the autumn is really the timing for having new vaccines available for use," he added.
According to the BBC, the team was already looking at updating the vaccine to make it more effective against the mutations that are being seen.
It comes after studies have shown that variants of Covid-19 with the worrying E484K mutation could make vaccines less effective,...
- 2/4/2021
- by IANS
- GlamSham
London, Feb 3 (Ians) The Oxford-AstraZeneca's Covid-19 vaccine showed 76 per cent efficacy against symptomatic infection for three months after a single dose, with protection maintained to the second dose, the pharmaceutical company said on Wednesday.
The primary analysis of the Phase 3 clinical trials, published as a preprint in The Lancet, also showed that with an inter-dose interval of 12 weeks or more, vaccine efficacy increased to 82 per cent.
"These new data provide an important verification of the interim data that has helped regulators such as the Mhra in the UK and elsewhere around the world to grant the vaccine emergency use authorisation," co-author Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial, said in a statement.
"It also helps to support the policy recommendation made by the Joint Committee on Vaccination and Immunisation for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that...
The primary analysis of the Phase 3 clinical trials, published as a preprint in The Lancet, also showed that with an inter-dose interval of 12 weeks or more, vaccine efficacy increased to 82 per cent.
"These new data provide an important verification of the interim data that has helped regulators such as the Mhra in the UK and elsewhere around the world to grant the vaccine emergency use authorisation," co-author Andrew Pollard, Chief Investigator of the Oxford Vaccine Trial, said in a statement.
"It also helps to support the policy recommendation made by the Joint Committee on Vaccination and Immunisation for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that...
- 2/3/2021
- by IANS
- GlamSham
A new vaccine developed by Oxford University and manufactured by AstraZeneca has shown to be up to 90% effective in preventing Covid-19, according to an interim analysis of trials in the U.K. and Brazil.
The results showed that the vaccine’s efficacy depended on the dosing regimen. The one that showed 90% efficacy saw patients first receiving a half dose of the vaccine, followed by a full dose at least one month later. The other dosing regiment, which was 62% effective, involved the patient receiving two full doses at least one month apart.
The results showed that the vaccine’s efficacy depended on the dosing regimen. The one that showed 90% efficacy saw patients first receiving a half dose of the vaccine, followed by a full dose at least one month later. The other dosing regiment, which was 62% effective, involved the patient receiving two full doses at least one month apart.
- 11/23/2020
- by Jon Blistein
- Rollingstone.com
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.